Anti-Canine IL-31 Reference Antibody (Tirnovetmab, RUO) (CV678016)

Name: Anti-Canine IL-31 Reference Antibody (Tirnovetmab, RUO)
Brand: abinScience
SKU: CV678016
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

CV678016

Description

Tirnovetmab (CV678016) is a research-grade recombinant antibody targeting IL-31. Produced in mammalian cells with native-like glycosylation.

Highlights

●Research Grade — For PK/PD studies, assay development, and ADA research.
●Native Glycosylation — Mammalian expression ensures native-like patterns.

Reactivité des espèces

Canine

Applications

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Espèce hôte

Canine

Clonalité

Monoclonal

Isotype

IgG2-Kappa

Système d'expression

Mammalian cells

Cible

IL-31, Interleukin-31, IL31

Niveau d'endotoxines

< 10 EU/mg

Pureté

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Numéro d'accès

C7G0W1

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
ELISA	1:2000-1:20000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Noms alternatifs

KIND-016, 2364504-80-1

Contexte

Tirnovetmab (KIND-016) is an antibody. Tirnovetmab can be used for experiment research.
• The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037
• IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760
• Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401
• A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353
• Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036
• Nemolizumab: First Approval., PMID:35834124
• Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249
• The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566
• Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098
• Targeting Interleukin-31 in Prurigo., PMID:37888922

Note

For research use only. Not suitable for clinical or therapeutic use.

Images